PRC
ABCL icon

Pearl River Capital’s AbCellera Biologics ABCL Stock Holding History

Pearl River Capital’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-32,458
Closed -$245K – 469
2023
Q1 		$245K Buy
32,458
+13,086
+68% +$119K 0.04% 441
2022
Q4 		$196K Sell
19,372
-43,002
-69% -$497K 0.03% 480
2022
Q3 		$617K Buy
62,374
+36,316
+139% +$398K 0.11% 250
2022
Q2 		$278K Buy
+26,058
New +$221K 0.07% 364

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Pearl River Capital's ABCL Position: Q2 2023 in Review

Pearl River Capital sold out of AbCellera Biologics (ABCL) in Q2 2023, closing a stake of 32,458 shares — an estimated $245K sold.

Pearl River Capital first reported a position in ABCL in Q2 2022 and held it in 4 quarters. The position peaked at $617K in Q3 2022. 169 funds tracked by Wall St. Rank hold ABCL as of Q2 2023.

  • Pearl River Capital reported no remaining AbCellera Biologics position as of Q2 2023 after selling out during the quarter.
  • Pearl River Capital sold 32,458 AbCellera Biologics shares in Q2 2023, an estimated $245K.
  • Pearl River Capital first reported a position in AbCellera Biologics in Q2 2022 and held it in 4 quarters.
  • Pearl River Capital's AbCellera Biologics position peaked at $617K in Q3 2022.
  • 169 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2023.

Based on Pearl River Capital's 13F filing for Q2 2023, filed 11 Aug 2023.